Insilico Medicine forecasted a sharp swing to profitability in the first half of 2026, signaling improving economics as its pipeline progresses. The AI drug developer said it expects net profit of about $33.5 million to $39.5 million for H1 2026 versus a $19.2 million net loss in the prior-year period. The company also projected record first-half revenue of roughly $102.5 million to $106.5 million, up about 272.7% to 287.3% year over year. Insilico attributed the jump to expanding partnerships and a drug pipeline that is increasingly reaching late-stage development, with its first program advancing to Phase III. Insilico’s full-year 2025 revenue declined to $56.239 million, down from $85.834 million in 2024, though it said discovery and pipeline-development mix shifted in ways that drove the later rebound. Cash and cash equivalents more than tripled last year to about $393.338 million, providing runway as it aims for “sustained profitability,” CEO Alex Zhavoronkov, PhD, said.